https://biotechcurrents.substack.com/archivedailyhttps://biotechcurrents.substack.com/aboutweeklyhttps://biotechcurrents.substack.com/p/biomatrix-device-drives-two-product2026-08-12monthlyhttps://biotechcurrents.substack.com/p/the-overlooked-mrna-bet-that-could2026-06-22monthlyhttps://biotechcurrents.substack.com/p/revenue-rising-for-demdodex-blepharitis2026-06-11monthlyhttps://biotechcurrents.substack.com/p/a-high-probability-shot-at-making2026-05-19monthlyhttps://biotechcurrents.substack.com/p/non-invasive-tech-delivers-impressive2026-04-29monthlyhttps://biotechcurrents.substack.com/p/the-biotech-perspective-432026-04-13monthlyhttps://biotechcurrents.substack.com/p/emerging-biotech-pushes-chips-forward2026-03-20monthlyhttps://biotechcurrents.substack.com/p/abivaxs-abvx-obefazimod-on-track2026-02-19monthlyhttps://biotechcurrents.substack.com/p/precision-medicine-emerges-in-narcolepsy2026-02-09monthlyhttps://biotechcurrents.substack.com/p/topsy-turvy-end-to-topsy-turvy-20252026-01-21monthlyhttps://biotechcurrents.substack.com/p/execution-capital-and-late-stage2025-12-22monthlyhttps://biotechcurrents.substack.com/p/clinical-stage-biopharmaceutical2025-11-25monthlyhttps://biotechcurrents.substack.com/p/leukemia-drug-gains-apparent-safety2025-11-11monthlyhttps://biotechcurrents.substack.com/p/buyout-candidates-thrive-rare-disease2025-10-28monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-422025-10-10monthlyhttps://biotechcurrents.substack.com/p/pushing-gene-editing-inside-the-body2025-10-08monthlyhttps://biotechcurrents.substack.com/p/company-takes-aim-at-new-cancer-indications2025-09-18monthlyhttps://biotechcurrents.substack.com/p/ideaya-idya-scores-phase-ii-win-in2025-09-12monthlyhttps://biotechcurrents.substack.com/p/fda-turns-back-telixs-otcpktlppf2025-09-02monthlyhttps://biotechcurrents.substack.com/p/the-fda-chill-continues-as-agency2025-08-22monthlyhttps://biotechcurrents.substack.com/p/company-on-track-to-be-fast-follower2025-08-05monthlyhttps://biotechcurrents.substack.com/p/fda-slaps-down-regenerons-regn-odronextamab2025-08-03monthlyhttps://biotechcurrents.substack.com/p/company-seeks-to-turn-around-treatment2025-07-29monthlyhttps://biotechcurrents.substack.com/p/company-seeks-to-boost-oncology-franchise2025-07-22monthlyhttps://biotechcurrents.substack.com/p/bids-for-verona-vrna-monogram-mgrm2025-07-16monthlyhttps://biotechcurrents.substack.com/p/after-brief-delay-fda-approves-kalvistas2025-07-10monthlyhttps://biotechcurrents.substack.com/p/new-data-could-redefine-the-market2025-07-01monthlyhttps://biotechcurrents.substack.com/p/clinical-trial-data-from-ascendis2025-06-19monthlyhttps://biotechcurrents.substack.com/p/atyr-pharmas-atyr-efzofitimod-aims2025-06-10monthlyhttps://biotechcurrents.substack.com/p/ideayas-idya-darovasertib-to-address2025-09-04monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-412025-06-02monthlyhttps://biotechcurrents.substack.com/p/orr-from-merus-nvs-nasdaqmrus-h-and2025-05-29monthlyhttps://biotechcurrents.substack.com/p/moonlakes-mltx-phase-iii-data-in2025-05-21monthlyhttps://biotechcurrents.substack.com/p/data-from-merus-nvs-mrus-petosemtamab2025-05-14monthlyhttps://biotechcurrents.substack.com/p/portfolio-update-the-floor-plan-takes2025-05-09monthlyhttps://biotechcurrents.substack.com/p/new-imaging-agent-targets-kidney2025-05-07monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-402025-04-27monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-392025-04-07monthlyhttps://biotechcurrents.substack.com/p/company-ramps-up-efforts-to-target2025-03-25monthlyhttps://biotechcurrents.substack.com/p/monogram-mgrm-holding-gains-after2025-03-19monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-382025-03-16monthlyhttps://biotechcurrents.substack.com/p/a-potential-first-in-class-oral-therapy2025-03-10monthlyhttps://biotechcurrents.substack.com/p/protagonist-ptgx-hits-on-all-key2025-03-05monthlyhttps://biotechcurrents.substack.com/p/an-off-the-shelf-immunotherapy-aims2025-03-10monthlyhttps://biotechcurrents.substack.com/p/merck-kgaa-bids-for-springworks-swtx2025-02-17monthlyhttps://biotechcurrents.substack.com/p/a-novel-wound-care-solution-emerging2025-02-12monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-372025-02-08monthlyhttps://biotechcurrents.substack.com/p/a-new-approach-to-immunotherapy-for2025-02-04monthlyhttps://biotechcurrents.substack.com/p/aesthetics-challenger-poised-for2025-01-29monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-362025-01-17monthlyhttps://biotechcurrents.substack.com/p/company-seeks-to-expand-mrnas-reach2025-01-09monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-352024-12-31monthlyhttps://biotechcurrents.substack.com/p/corcept-cort-falls-short-in-als-while2024-12-13monthlyhttps://biotechcurrents.substack.com/p/shares-of-new-amsterdam-nams-climb2024-12-11monthlyhttps://biotechcurrents.substack.com/p/companys-new-approach-in-addressing2024-12-09monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-342024-12-06monthlyhttps://biotechcurrents.substack.com/p/janux-janx-data-shines-kura-kura2024-12-03monthlyhttps://biotechcurrents.substack.com/p/novocure-nvcr-inari-nari-shares-rise2024-12-03monthlyhttps://biotechcurrents.substack.com/p/shares-of-applied-thera-aplt-crash2024-12-02monthlyhttps://biotechcurrents.substack.com/p/advancing-cancer-treatment-a-companys2024-11-25monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-332024-11-23monthlyhttps://biotechcurrents.substack.com/p/perspectives-catx-radiopharma-drug2024-11-22monthlyhttps://biotechcurrents.substack.com/p/pioneering-company-advances-growth2024-11-19monthlyhttps://biotechcurrents.substack.com/p/centessa-cnta-waves-white-flag-on2024-11-14monthlyhttps://biotechcurrents.substack.com/p/biotech-aims-to-win-over-surgeons2024-11-13monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-322024-11-08monthlyhttps://biotechcurrents.substack.com/p/complimentary-new-amsterdam-repositions2024-10-28monthlyhttps://biotechcurrents.substack.com/p/alto-anro-flops-opening-night2024-10-24monthlyhttps://biotechcurrents.substack.com/p/company-turns-around-immature-cancer2024-10-21monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-312024-10-19monthlyhttps://biotechcurrents.substack.com/p/experts-predict-high-success-rate2024-10-21monthlyhttps://biotechcurrents.substack.com/p/key-surrogate-catalyst-at-neuroscience2024-10-09monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-302024-10-04monthlyhttps://biotechcurrents.substack.com/p/biohavens-bhvn-troriluzole-scores2024-10-02monthlyhttps://biotechcurrents.substack.com/p/erasca-seeks-to-erase-cancers-most2024-09-30monthlyhttps://biotechcurrents.substack.com/p/zenas-seeks-to-establish-obexelimab2024-09-23monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-292024-09-20monthlyhttps://biotechcurrents.substack.com/p/centessas-serpinpc-to-offer-flexible2024-09-17monthlyhttps://biotechcurrents.substack.com/p/nuvalent-nuvl-posts-impressive-data2024-09-16monthlyhttps://biotechcurrents.substack.com/p/arrivent-avbp-delivers-in-proof-of2024-09-11monthlyhttps://biotechcurrents.substack.com/p/actuate-enters-public-market-with2024-09-09monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-282024-09-09monthlyhttps://biotechcurrents.substack.com/p/vaxcyte-pcvx-data-shines-in-game2024-09-05monthlyhttps://biotechcurrents.substack.com/p/syndax-sndx-gains-approval-for-axatilimab2024-08-28monthlyhttps://biotechcurrents.substack.com/p/alto-advances-new-psychiatric-drugs2024-08-26monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-272024-08-23monthlyhttps://biotechcurrents.substack.com/p/phase-ii-data-could-drive-springworks2024-08-19monthlyhttps://biotechcurrents.substack.com/p/lenz-thera-lenz-files-nda-for-presbyopia2024-08-14monthlyhttps://biotechcurrents.substack.com/p/lead-drug-from-janux-to-join-wave2024-08-12monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-262024-08-10monthlyhttps://biotechcurrents.substack.com/p/summer-doldrums-drag-down-approval2024-08-07monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-252024-07-27monthlyhttps://biotechcurrents.substack.com/p/agios-nears-approval-of-second-drug2024-07-22monthlyhttps://biotechcurrents.substack.com/p/investors-unenthused-with-phase-ii2024-07-17monthlyhttps://biotechcurrents.substack.com/p/perspective-thera-puts-the-pieces2024-07-15monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-242024-07-12monthlyhttps://biotechcurrents.substack.com/p/commenting-on-fda-complete-response2024-07-02monthlyhttps://biotechcurrents.substack.com/p/verona-rocket-face-pdufa-decisions2024-06-24monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-232024-06-21monthlyhttps://biotechcurrents.substack.com/p/intra-cellular-rises-again-on-caplyta2024-06-19monthlyhttps://biotechcurrents.substack.com/p/aerovate-trial-misses-primary-endpoint2024-06-17monthlyhttps://biotechcurrents.substack.com/p/4d-molecular-applies-therapeutic2025-08-21monthlyhttps://biotechcurrents.substack.com/p/prothenas-al-amyloidosis-drug-finds2024-06-11monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-222024-06-07monthlyhttps://biotechcurrents.substack.com/p/astrazenecas-24-billion-fusion-acquisition2024-06-06monthlyhttps://biotechcurrents.substack.com/p/lexeos-gene-therapy-drug-could-become2024-06-03monthlyhttps://biotechcurrents.substack.com/p/merus-shares-rise-on-antibody-data2024-05-28monthlyhttps://biotechcurrents.substack.com/p/vicore-pharmas-phase-iia-data-shines2024-05-21monthlyhttps://biotechcurrents.substack.com/p/nuvalents-niche-lung-cancer-drug2024-05-20monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-212024-05-18monthlyhttps://biotechcurrents.substack.com/p/corcepts-dazucorilant-seeks-to-tame2024-05-13monthlyhttps://biotechcurrents.substack.com/p/biohavens-decade-long-attention-to2024-05-20monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-202024-05-03monthlyhttps://biotechcurrents.substack.com/p/merus-cancer-drug-zeno-may-reach2024-04-29monthlyhttps://biotechcurrents.substack.com/p/day-one-bio-rises-33-after-accelerated2024-04-24monthlyhttps://biotechcurrents.substack.com/p/two-syndax-drugs-may-receive-fda2024-04-22monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-192024-04-19monthlyhttps://biotechcurrents.substack.com/p/intra-cellular-kiniksa-hit-on-catalysts2024-04-17monthlyhttps://biotechcurrents.substack.com/p/vaxcyte-bets-against-itself-in-pneumonia2024-04-15monthlyhttps://biotechcurrents.substack.com/p/lenz-thera-sees-a-near-term-opportunity2024-04-08monthlyhttps://biotechcurrents.substack.com/p/effector-therapeutics-cancer-drug2024-04-08monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-18-3d52024-04-05monthlyhttps://biotechcurrents.substack.com/p/disc-medicines-bitopertin-falls-short2024-04-02monthlyhttps://biotechcurrents.substack.com/p/intra-cellulars-push-into-mdd-with2024-04-17monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-182024-03-22monthlyhttps://biotechcurrents.substack.com/p/astrazeneca-snaps-up-fusion-for-242024-03-20monthlyhttps://biotechcurrents.substack.com/p/portfolio-update-harmony-reschedules2024-03-20monthlyhttps://biotechcurrents.substack.com/p/inaris-flowtriever-catheter-nudges2024-03-18monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-applied-theras-govorestat2024-04-17monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-172024-03-08monthlyhttps://biotechcurrents.substack.com/p/the-effect-of-effectors-under-the2024-04-05monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-oculars-long-term2024-04-17monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-162024-02-23monthlyhttps://biotechcurrents.substack.com/p/kalvista-hits-endpoints-in-hae-trial2024-02-18monthlyhttps://biotechcurrents.substack.com/p/pdufa-decision-to-position-abeonas2024-02-12monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-152024-02-09monthlyhttps://biotechcurrents.substack.com/p/arrivents-furmonertinib-builds-bridge2024-03-08monthlyhttps://biotechcurrents.substack.com/p/mineralys-lorundrostat-aims-to-treat2024-01-29monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-142024-01-26monthlyhttps://biotechcurrents.substack.com/p/harmonys-recently-acquired-synthetic2024-02-05monthlyhttps://biotechcurrents.substack.com/p/2024-publication-schedule2024-01-14monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-132024-03-14monthlyhttps://biotechcurrents.substack.com/p/portfolio-update-sanacurrents-closing2024-01-10monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-fusions-prostate2024-03-20monthlyhttps://biotechcurrents.substack.com/p/biotech-currents-catalyst-table2024-03-20monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-122024-01-01monthlyhttps://biotechcurrents.substack.com/p/bristol-myers-buys-rayzebio-for-412024-03-19monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-disc-medicines-mid2024-01-07monthlyhttps://biotechcurrents.substack.com/p/fda-approves-crspr-theras-sickle2024-01-07monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-veronas-ensifentrine2024-01-07monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-112023-12-08monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-kiniksas-under-the2024-04-17monthlyhttps://biotechcurrents.substack.com/p/xenon-rises-on-positive-data-fda2024-01-07monthlyhttps://biotechcurrents.substack.com/p/portfolio-update-verve-eton-and-x42024-01-07monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-pending-fda-approval2024-01-07monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-connect-biopharmas2024-01-07monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-102023-12-28monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-rocket-pharmaceuticals2024-01-07monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-etons-growth-in-the2024-01-07monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-92023-12-28monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-rayzebios-ryzb-emerging2024-03-19monthlyhttps://biotechcurrents.substack.com/p/structure-theras-shares-continue2024-01-07monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-sweden-based-vicores2024-01-07monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-82023-10-13monthlyhttps://biotechcurrents.substack.com/p/syndaxs-strong-phase-ii-data-for2024-01-07monthlyhttps://biotechcurrents.substack.com/p/syndaxs-strong-phase-ii-data-for-9242024-01-07monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-pliants-second-anti2024-01-07monthlyhttps://biotechcurrents.substack.com/p/structure-theras-shares-surge-after2024-01-07monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-72023-09-29monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-aerovates-well-financed2024-01-07monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-cogents-pivot-and2024-01-07monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-62023-09-15monthlyhttps://biotechcurrents.substack.com/p/coya-thera-reports-positive-data2024-01-06monthlyhttps://biotechcurrents.substack.com/p/acelyrins-rare-skin-disorder-drug2024-01-06monthlyhttps://biotechcurrents.substack.com/p/picture-perfect-phase-iii-data-pushes2024-01-06monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-xenons-transition2024-01-07monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-52023-09-08monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-centessas-novel-approach2024-01-07monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-structure-theras2024-01-06monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-42023-08-25monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-alectors-immuno-neurology2024-01-07monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-32023-08-14monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-crinetics-paltusotine2024-01-07monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective-22023-08-14monthlyhttps://biotechcurrents.substack.com/p/china-based-hutchmeds-colorectal2024-01-07monthlyhttps://biotechcurrents.substack.com/p/the-friday-biotech-perspective2023-08-14monthlyhttps://biotechcurrents.substack.com/p/fda-approval-for-tarsus-eye-drug2023-12-28monthlyhttps://biotechcurrents.substack.com/p/kalvista-pharmaceuticals-inc-nasdaqkalv2024-01-07monthlyhttps://biotechcurrents.substack.com/p/a-one-time-medicine-to-prevent-heart2024-01-07monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-closing-coverage-on2024-01-06monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-acelyrins-fast-follower2024-01-07monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-coya-theras-treg2024-01-07monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-the-first-crspr-drug2024-01-07monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-ventyxs-rising-phase2024-01-07monthlyhttps://biotechcurrents.substack.com/p/aadi-bioscience-data-not-overwhelming2024-01-06monthlyhttps://biotechcurrents.substack.com/p/akebia-sees-a-path-forward-for-vadadustat2024-01-06monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-structure-theras-fdc2024-01-06monthlyhttps://biotechcurrents.substack.com/p/stellar-data-sends-x4-pharma-xfor2024-01-17monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-the-fda-decision2024-01-07monthlyhttps://biotechcurrents.substack.com/p/immunogen-imgn-soars-on-ovarian-cancer2023-12-28monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-immatics-promising2024-01-07monthlyhttps://biotechcurrents.substack.com/p/welcome-to-biotech-currents2024-01-01monthlyhttps://biotechcurrents.substack.com/p/astellas-swoops-in-for-59-billion2024-01-06monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-verricas-drug-device2024-03-11monthlyhttps://biotechcurrents.substack.com/p/closing-coverage-in-precision-biosciences2024-01-06monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-viridians-rising2024-01-07monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-closing-out-coverage2024-01-06monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-closing-out-aldeyra2024-01-06monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-immunogens-elahere2024-01-07monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-ptc-therapeutics2024-01-07monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-fda-decision-for2024-01-07monthlyhttps://biotechcurrents.substack.com/p/scholar-rocks-phase-ii-topaz-data2024-01-06monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-scholar-rocks-improving2024-01-07monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-wave-life-sciences2024-01-07monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-pdufa-decision-for-6f12024-01-07monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-the-fdas-lifejacket2024-01-02monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-equilliums-potential2024-01-02monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-pdufa-decision-for2024-01-06monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-newly-listed-acrivons2024-01-06monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-precision-bios-second2024-01-06monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-aadi-bios-expansion2024-01-06monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-syndaxs-rising-drug2024-01-06monthlyhttps://biotechcurrents.substack.com/p/sanacurrents-on-x4-pharmaceuticals2024-01-06monthlyhttps://biotechcurrents.substack.com/p/coming-soon2023-05-05monthly